Table 3 Clinical, histopathological and metabolic features of NF-PNETs
18F-FDG-positive SUVmax range 3.0–8.6 | 18F-FDG-negative SUVmax range 0.8–3.2 | P | 68Ga-DOTANOC-positive SUVmax range 8.7–104.7 | 68Ga-DOTANOC-negative SUVmax 4.4 | P | |
|---|---|---|---|---|---|---|
Sex | 1.000 | 1.000 | ||||
Male | 7/11 (64) | 13/20 (65) | 19/30 | 1/1 | ||
Female | 4/11 (36) | 7/20 (35) | 11/30 | 0/1 | ||
Age, years | 67 (38–78) | 68 (50–71) | 1.000 | 66 (47–72) | 70 | 0.903 |
Primary tumor size, mm | 33 (23–90) | 20 (13–30) | 0.023 | 24 (14-38) | 33 | 0.581 |
Asymptomatic | 8/11 (73) | 20/20 (100) | 0.037 | 27/30 | 1/1 | 1.000 |
CgA | 0.258 | 0.516 | ||||
Strongly positive | 2/11 (18) | 1/20 (5) | 3/30 | 0/1 | ||
Weakly positive | 6/11 (55) | 9/20 (45) | 15/30 | 0/1 | ||
Negative | 3/11 (27) | 11/20 (50) | 12/30 | 1/1 | ||
Location | 0.630 | 1.000 | ||||
Head | 6/11 (55) | 6/20 (30) | 11/30 | 1/1 | ||
Body | 0/11 (0) | 2/20 (10) | 2/30 | 0/1 | ||
Tail | 3/11 (27) | 7/20 (35) | 10/30 | 0/1 | ||
Multifocal | 2/11 (18) | 5/20 (25) | 7/30 | 0/1 | ||
Grade* | 0.023 | 1.000 | ||||
G1 | 3/9 (33) | 13/16 (81) | 15/24 | 1/1 | ||
G2 | 5/9 (56) | 3/16 (19) | 8/24 | 0/1 | ||
G3 | 1/9 (11) | 0/16 (0) | 1/24 | 0/1 | ||
Ki-67 | 4.0 (1.5–11.0) | 2.0 (1.0–2.5) | 0.051 | 2.0 (1.0–4.5) | 1.0 | 0.384 |
68Ga-DOTANOC-positive | 10/11 (91%) | 20/20 (100%) | 0.355 | |||
18FDG-positive | 10/30 (33%) | 1/1 (100%) | 0.355 | |||
LN+‰ | 2/8 (33) | 4/11 (36) | 1.000 | 5/30 | 1/1 | 0.316 |